Home GPCR & G Protein Prostaglandin Receptor agonist Tafluprost

research use only

Tafluprost Prostaglandin Receptor agonist

Cat.No.S4851

Tafluprost (AFP-168,MK2452) is a novel prostaglandin analog with a high affinity for the fluoroprostaglandin (FP) receptor PGF2α. A prostanoid selective FP receptor agonist.
Tafluprost Prostaglandin Receptor agonist Chemical Structure

Chemical Structure

Molecular Weight: 452.53

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Chemical Information, Storage & Stability

Molecular Weight 452.53 Formula

C25H34F2O5

 Storage (From the date of receipt) 2 years  -20°C  liquid
CAS No. 209860-87-7 -- Storage of Stock Solutions

Synonyms AFP-168,MK2452 Smiles CC(C)OC(=O)CCCC=CCC1C(CC(C1C=CC(COC2=CC=CC=C2)(F)F)O)O

Solubility

In vitro
Batch:

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo
Batch:

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC50/Ki
PGF2α [1]
References

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04828057 Completed
Ocular Surface Disease|Primary Open Angle Glaucoma
Santen Pharmaceutical (Taiwan) Co. LTD
 September 1 2021 --
NCT03612817 Completed
Glaucoma Open-Angle
Aristotle University Of Thessaloniki|Santen Oy
 January 2017 Phase 4
NCT02102750 Completed
Glaucoma|Ocular Hypertension
Santen Oy
 June 2014 Phase 1
NCT03104621 Completed
Primary Open-angle Glaucoma
Gangnam Severance Hospital
 March 2013 Phase 4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.